James W. Kiser, the President and Chief Executive Officer of the Bank, will assume those same duties with the Company on March 31, 2024.
Departed
Peter Faricy
Chief Executive Officer
SUNPOWER CORP
Effective
2024-02-26
Filed
February 27, 2024, 6:59 PM ET
On February 26, 2024, the Board of Directors (the “Board”) of SunPower Corporation (the “Company”) accepted the resignation of Peter Faricy, the Company’s Chief Executive Officer and principal executive officer, effective as of February 26, 2024.
David A. Burwick, President and Chief Executive Officer, has decided to step down from his position and as a member of the Company’s Board of Directors, effective March 31, 2024.
As of the Effective Date, Mark Mauldin will cease serving as Interim Chief Financial Officer and will continue to serve in his role as Chief Accounting Officer.
On February 27, 2024, Silicon Laboratories Inc. (the “Company”) announced the appointment of Dean Butler as Senior Vice President and Chief Financial Officer, effective May 15, 2024
Departed
James Alt
Chief Executive Officer
Legacy IMBDS, Inc.
Filed
February 27, 2024, 6:59 PM ET
Each of the Company’s directors (Darryl Porter, Landel Hobbs, Jill Krueger, Alan Aldworth, Aaron Reitkopf, Michael Friedman, Eyal Lalo, Steve Panagos, and Jill Frizzley), and the Company’s remaining officer, James Alt, will cease to be directors and officers of the Company on the Effective Date.
Effective upon Mr. Butler’s resignation, Michael Hurlston, President and Chief Executive Officer of the Company, will serve as the Company’s principal financial officer on an interim basis.
On February 21, 2024, Dean Butler, the Senior Vice President and Chief Financial Officer of Synaptics Incorporated (the “Company”), informed the Company that he has decided to resign, effective February 26, 2024.
Appointed
(interim)
Thomas H. King
Interim Chief Financial Officer
View, Inc.
Effective
2024-02-21
Filed
February 27, 2024, 6:59 PM ET
On February 21, 2024, the Board appointed Thomas H. King to serve as Interim Chief Financial Officer, effective immediately.
On February 26, 2024, D. Andrew Borrmann, Chief Financial Officer of Southern First Bancshares, Inc. (the “Company”) and Southern First Bank (the “Bank” and together with the Company, the “Employer”), notified the Employer that he is resigning from his roles with the Employer , effective March 29, 2024 .
Mr. Atwood was appointed as the Company’s Chief Executive Officer
Departed
Michael Cammarata
President and Chief Executive Officer
Neptune Wellness Solutions Inc.
Effective
2024-02-23
Filed
February 27, 2024, 6:59 PM ET
its President and Chief Executive Officer, Michael Cammarata, and its Executive Vice President and Chief Legal Officer, John Wirt, have been placed on mandatory unpaid leave, effective February 23, 2024
Appointed
Nirav Tolia
Chief Executive Officer, President, and Chairperson of the Board
Effective February 26, 2024, Benjamin G. S. Fowke, III, who has served on the Board since February 2022, was appointed Interim Chief Executive Officer and President.
On February 20, 2024, following discussions with Julia A. Sloat, Chair, Chief Executive Officer and President of American Electric Power Company, Inc. (“Company”), the Board of Directors (the “Board”) of the Company determined to remove Ms. Sloat from her roles as Chair, Chief Executive Officer and President of the Company, effective February 25, 2024.
On February 26, 2024, the Company announced that Michaela (Mika) M. Ware, 52, has been appointed to the position of Senior Vice President and Chief Financial Officer effective as of June 27, 2024.
Departed
Joseph G. Taylor
Executive Vice President and Chief Financial Officer
On February 22, 2024, Joseph G. Taylor, 65, notified Brinker International, Inc. (the “Company”) that he will retire from his position of Executive Vice President and Chief Financial Officer effective as of June 26, 2024
On February 24, 2024, the Board of Directors (the “Board”) of Seres Therapeutics, Inc. (the “Company”) appointed Marella Thorell to succeed David Arkowitz as the Company’s Executive Vice President and Chief Financial Officer, effective as of the commencement of her employment with the Company, which is expected to be on or about March 25, 2024 (the “Effective Date”), following Mr. Arkowitz’s retirement effective as of March 15, 2024 (the “Retirement Date”).
On February 21, 2024, MarketAxess Holdings Inc. (the “Company”) appointed Ilene Fiszel Bieler as Chief Financial Officer of the Company and to act as the Company’s principal financial officer for purposes of the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”), effective on her start date with the Company, which is currently expected to be May 22, 2024 (the “Effective Date”).
Effective as of immediately following the Effective Time, Mr. Dundas will be terminated from his employment as President and Chief Executive Officer of Enerplus
Departed
William B. Rutherford
Executive Vice President and Chief Financial Officer
William B. Rutherford intends to retire as Executive Vice President and Chief Financial Officer, effective May 1, 2024, and will therefore not participate in the Executive Officer PEP.
On February 26, 2024, Northwest Bancshares, Inc. (the “Company”) and its wholly-owned subsidiary, Northwest Bank, appointed Douglas M. Schosser Chief Financial Officer, effective March 18, 2024.
On February 20, 2024, Timothy Pitoniak informed Issuer Direct Corporation (the “ Company ”) of his resignation as Chief Financial Officer of the Company, effective March 8, 2024 (the “ Effective Date” ).
Appointed
(interim)
Steve Knerr
interim Principal Accounting Officer and interim Chief Financial Officer
the Board intends to appoint Steve Knerr, the Company’s current Vice President of Finance and Controller, as its interim Principal Accounting Officer and interim Chief Financial Officer.
On February 23, 2024, the Board appointed Eric Mosser, a current Senior Advisor to the Company and the Chief Executive Officer of Kaival International Brands, LLC, a wholly owned subsidiary of the Company, as the Company’s President and Interim Chief Executive Officer, to serve in such capacity until a successor is duly appointed and approved by the Board.
On February 22, 2024, Barry M. Hopkins, the Interim Chief Executive Officer, President, and Director of the Company, provided written notice to the Company’s Board of Directors (the “Board”) of his resignation, effectively immediately.
On February 20, 2024, Thomas Metzler, the Chief Financial Officer, Secretary and Treasurer of the Company, provided written notice to the Company’s Board of his resignation, effectively immediately.
On February 22, 2024, Envista Holdings Corporation (the “Company”) and Amir Aghdaei, the President and Chief Executive Officer of the Company, entered into a transition letter agreement (the “Transition Agreement”), setting forth the terms of Mr. Aghdaei’s anticipated transition from his position as the Company’s President and Chief Executive Officer.
Appointed
R. Ryan Richards
Executive Vice President and Chief Financial Officer of the Company
ZION ·
ZIONS BANCORPORATION, NATIONAL ASSOCIATION /UT/
Effective
2024-04-01
Filed
February 23, 2024, 6:59 PM ET
R. Ryan Richards will succeed Mr. Burdiss as Executive Vice President and Chief Financial Officer of the Company, having previously served as the Company’s Senior Vice President and Corporate Controller since 2021.
unanimously appointed Jackson Hsieh to fill the newly created vacancy, effective concurrently with his appointment to the role of Chief Executive Officer and President on March 1, 2024.
Appointed
(interim)
Forrest Hoffmaster
interim Chief Executive Officer
Medicine Man Technologies, Inc.
Effective
2024-02-21
Filed
February 23, 2024, 6:59 PM ET
On February 21, 2024 (“Appointment Date”), the Board appointed Forrest Hoffmaster, the Company’s Chief Financial Officer, as interim Chief Executive Officer of the Company.
Departed
Nirup Krishnamurthy
Chief Executive Officer
Medicine Man Technologies, Inc.
Effective
2024-02-20
Successor
Forrest Hoffmaster
Filed
February 23, 2024, 6:59 PM ET
On February 20, 2024, the Company received notice of the resignation of Nirup Krishnamurthy as a member of the Company’s board of directors (the “Board”) and Chief Executive Officer of the Company
appointed Kimberly A. Fields, currently the Company’s President and Chief Operating Officer, to serve as President and Chief Executive Officer of the Company, effective as of July 1, 2024.
Departed
Stephen T. Wills
Chief Financial Officer
Cactus Acquisition Corp. 1 Ltd
Effective
2024-02-23
Filed
February 23, 2024, 6:59 PM ET
the following officers submitted the resignation of their respective offices: Ofer Gonen as Chief Executive Officer, and Stephen T. Wills as Chief Financial Officer.
Departed
Ofer Gonen
Chief Executive Officer
Cactus Acquisition Corp. 1 Ltd
Effective
2024-02-23
Filed
February 23, 2024, 6:59 PM ET
the following officers submitted the resignation of their respective offices: Ofer Gonen as Chief Executive Officer, and Stephen T. Wills as Chief Financial Officer.
Role change
Jason Dubinsky
principal accounting officer (in addition to Chief Financial Officer)
the Company designated Jason Dubinsky (age 50) as principal accounting officer, in addition to his current role as Chief Financial Officer (and principal financial officer) of the Company.
On February 16, 2024, the Company and Mr. Charles Scheiwe agreed to the stepping down of Mr. Scheiwe as the Company’s Chief Financial Officer and Secretary, including all positions with the Company and Flux Power, Inc., a wholly-owned subsidiary of the Company (“Flux”) and transitioning to a consultant for the Company (“the “Transition”), effective March 1, 2024 (the “Separation Date”).
On February 22, 2024, as a result of Mr. Scheiwe’s stepping down in connection with the Transition, the Board appointed Mr. Kevin S. Royal as Chief Financial Officer and Corporate Secretary, to be effective March 4, 2024.
Departed
Richard A. Fair
President and Chief Executive Officer
BELLICUM PHARMACEUTICALS, INC
Effective
2024-02-23
Successor
Dave Maggio
Filed
February 23, 2024, 6:59 PM ET
Mr. Richard A. Fair resigned as President and Chief Executive Officer of the Company
Appointed
Dave Maggio
Chief Executive Officer
BELLICUM PHARMACEUTICALS, INC
Effective
2024-02-23
Filed
February 23, 2024, 6:59 PM ET
the Board appointed Dave Maggio to the position of Chief Executive Officer
On February 20, 2024, Christopher Meyer, the Company’s Chief Financial Officer notified the Company of his intention to retire from the Company in 2024.
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.